Is axitinib the preferred second-line agent for renal cell carcinoma?

Bradford R. Hirsch, Daniel J. George
  • Community Oncology, July 2012, Elsevier
  • DOI: 10.1016/j.cmonc.2012.07.001

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/j.cmonc.2012.07.001

The following have contributed to this page: Dr Bradford R Hirsch